Quarterly ResultMay 19, 2026, 05:12 PM
Oramed Sells POD Tech to Lifeward; Q1 Net Income $38.31M
AI Summary
Oramed Pharmaceuticals Inc. reported a significant net income of $38.31 million for the three months ended March 31, 2026, a substantial improvement from a net loss of $7.64 million in the prior year. This was largely driven by a $5.82 million gain from the sale of its POD technology platform to Lifeward Ltd. and $2.00 million income from the Medicox License Agreement. The company also made a strategic investment in Lifeward, receiving equity, warrants, and senior secured convertible notes, and paid $10.36 million in dividends.
Key Highlights
- Oramed divested its POD technology platform to Lifeward Ltd. for equity, warrants, and revenue-sharing.
- Recognized a $5.82 million gain on the sale of the POD technology IP.
- Reported Q1 2026 net income of $38.31 million, compared to a net loss of $7.64 million in Q1 2025.
- Basic income per share was $0.94 in Q1 2026, up from a loss of $0.19 in Q1 2025.
- Financial income (loss), net significantly increased to $44.85 million in Q1 2026 from a loss of $2.56 million in Q1 2025.
- Recognized $2.00 million in other income from the Medicox License Agreement.
- Cash and cash equivalents decreased to $13.20 million as of March 31, 2026, from $45.95 million at December 31, 2025.
- Paid dividends of $10.36 million during the quarter.
Price Impact